Bdparib 300mg Tablet 60’s

Bdparib 300mg Tablet contains Rucaparib, a PARP inhibitor that helps treat certain cancers by preventing DNA repair in cancer cells, slowing or stopping their growth. Primarily prescribed for advanced ovarian, fallopian tube, and peritoneal cancers, Bdparib 300mg works as maintenance therapy for patients with a partial or complete response to platinum-based chemotherapy, helping to maintain remission.

Uses:

• Maintenance therapy for ovarian, fallopian tube, and peritoneal cancers
• Effective after response to platinum-based chemotherapy

Side Effects:

• Common: Fatigue, nausea, constipation, taste changes, and loss of appetite
• Serious: Low blood cell counts, liver enzyme changes, increased risk of leukemia—patients should be closely monitored by their healthcare provider

Key Features:

• Contains Rucaparib, targeting DNA repair in cancer cells
• Designed to maintain remission in advanced ovarian and related cancers
• Convenient oral tablet formulation for easy at-home use

References:

• DrugBank Database, Rucaparib details, https://go.drugbank.com/drugs/DB12332
• Mayo Clinic, Rucaparib Oral Route, [Accessed on DATE], https://www.mayoclinic.org/drugs-supplements/rucaparib-oral-route/description/drg-20406019